

# Market Announcement

21 July 2025

---

## Amplia Therapeutics Limited (ASX: ATX) – Trading Halt

Trading in the securities of Amplia Therapeutics Limited ('ATX') will be halted at the request of ATX, pending the release of an announcement by ATX.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Wednesday, 23 July 2025; or
- the release of the announcement to the market.

ATX's request for a trading halt is attached below for the information of the market.

### Issued by

ASX Compliance

21 July 2025

**AMPLIA THERAPEUTICS LIMITED (ASX: ATX) - REQUEST FOR TRADING HALT**

Pursuant to Listing Rule 17.1, Amplia Therapeutics Limited ACN 165 160 841 (the **Company** or **Amplia**) requests that ASX grant an immediate trading halt for all of Amplia's securities.

In accordance with Listing Rule 17.1, the Company advises that:

- the trading halt is requested pending an announcement regarding a capital raising, to be undertaken by way of a share placement and share purchase plan (**Offer**);
- the trading halt is required to enable the Offer to be undertaken in an orderly manner;
- Amplia requests that the trading halt remain in place until the earlier of such time as it makes an announcement to the market in relation to the outcome of the Offer and the commencement of trading on Wednesday, 23 July 2025; and
- Amplia is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market or ASX about the trading halt.

This trading halt request was authorised for release by the Board of Amplia Therapeutics Limited.

- End -

**Investor Contact:**

Dr Chris Burns  
Chief Executive Officer  
[chris@ampliatx.com](mailto:chris@ampliatx.com)

**Media Contact:**

HACK Director, Haley Chartres  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 423 139 163

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit [www.ampliatx.com](http://www.ampliatx.com) and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/amplia-therapeutics).